Cas no 1005630-27-2 (2-(4-bromo-3-methyl-1H-pyrazol-1-yl)propanehydrazide)
2-(4-bromo-3-methyl-1H-pyrazol-1-yl)propanehydrazide Chemical and Physical Properties
Names and Identifiers
-
- 2-(4-Bromo-3-methyl-pyrazol-1-yl)-propionic acid hydrazide
- 2-(4-bromo-3-methyl-1H-pyrazol-1-yl)propanehydrazide
- 2-(4-bromo-3-methylpyrazol-1-yl)propanehydrazide
- 2-(4-bromo-3-methyl-1H-pyrazol-1-yl)propanohydrazide
- 1005630-27-2
- AKOS000308218
- BBL038880
- EN300-228392
- STK312674
- CS-0282507
- 2-(4-bromo-3-methylpyrazolyl)propanohydrazide
-
- MDL： MFCD03419642
- Inchi： 1S/C7H11BrN4O/c1-4-6(8)3-12(11-4)5(2)7(13)10-9/h3,5H,9H2,1-2H3,(H,10,13)
- InChI Key： RPOGWCUSHRFDEO-UHFFFAOYSA-N
- SMILES： BrC1C(C)=NN(C=1)C(C(NN)=O)C
Computed Properties
- Exact Mass: 246.01162g/mol
- Monoisotopic Mass: 246.01162g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 3
- Heavy Atom Count: 13
- Rotatable Bond Count: 2
- Complexity: 201
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 1
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Molecular Weight: 247.09g/mol
- XLogP3: 0.4
- Topological Polar Surface Area: 72.9?2
Experimental Properties
- Density: 1.7±0.1 g/cm3
- Boiling Point: 421.5±35.0 °C at 760 mmHg
- Flash Point: 208.7±25.9 °C
- Vapor Pressure: 0.0±1.0 mmHg at 25°C
2-(4-bromo-3-methyl-1H-pyrazol-1-yl)propanehydrazide Security Information
- Signal Word：warning
- Hazard Statement： H303+H313+H333
- Warning Statement： P264+P280+P305+P351+P338+P337+P313
- Safety Instruction： H303+H313+H333
- Storage Condition：storage at -4℃ (1-2weeks), longer storage period at -20℃ (1-2years)
2-(4-bromo-3-methyl-1H-pyrazol-1-yl)propanehydrazide Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| Fluorochem | 026781-1g |
2-(4-Bromo-3-methyl-1H-pyrazol-1-yl)propionic acid hydrazide |
1005630-27-2 | 1g |
￡210.00 | 2022-03-01 | ||
| Fluorochem | 026781-5g |
2-(4-Bromo-3-methyl-1H-pyrazol-1-yl)propionic acid hydrazide |
1005630-27-2 | 5g |
￡591.00 | 2022-03-01 | ||
| abcr | AB498353-250 mg |
2-(4-Bromo-3-methyl-1H-pyrazol-1-yl)propanohydrazide |
1005630-27-2 | 250MG |
€198.50 | 2022-03-24 | ||
| abcr | AB498353-500 mg |
2-(4-Bromo-3-methyl-1H-pyrazol-1-yl)propanohydrazide |
1005630-27-2 | 500MG |
€264.80 | 2022-03-24 | ||
| abcr | AB498353-1 g |
2-(4-Bromo-3-methyl-1H-pyrazol-1-yl)propanohydrazide |
1005630-27-2 | 1g |
€309.00 | 2022-03-24 | ||
| abcr | AB498353-5 g |
2-(4-Bromo-3-methyl-1H-pyrazol-1-yl)propanohydrazide |
1005630-27-2 | 5g |
€752.70 | 2022-03-24 | ||
| SHANG HAI HAO HONG Biomedical Technology Co., Ltd. | 1353177-50mg |
2-(4-Bromo-3-methyl-1h-pyrazol-1-yl)propanehydrazide |
1005630-27-2 | 95% | 50mg |
￥1382 | 2023-04-17 | |
| SHANG HAI HAO HONG Biomedical Technology Co., Ltd. | 1353177-100mg |
2-(4-Bromo-3-methyl-1h-pyrazol-1-yl)propanehydrazide |
1005630-27-2 | 95% | 100mg |
￥1572 | 2023-04-17 | |
| SHANG HAI HAO HONG Biomedical Technology Co., Ltd. | 1353177-250mg |
2-(4-Bromo-3-methyl-1h-pyrazol-1-yl)propanehydrazide |
1005630-27-2 | 95% | 250mg |
￥2405 | 2023-04-17 | |
| SHANG HAI HAO HONG Biomedical Technology Co., Ltd. | 1353177-500mg |
2-(4-Bromo-3-methyl-1h-pyrazol-1-yl)propanehydrazide |
1005630-27-2 | 95% | 500mg |
￥4939 | 2023-04-17 |
2-(4-bromo-3-methyl-1H-pyrazol-1-yl)propanehydrazide Related Literature
-
Richa Sardessai,Shobhana Krishnaswamy,Mysore S. Shashidhar CrystEngComm, 2012,14, 8010-8016
-
Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
-
Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159
-
Tong Xu,Dongwei Ma,Chengbo Li,Qian Liu,Siyu Lu,Abdullah M. Asiri,Chun Yang,Xuping Sun Chem. Commun., 2020,56, 3673-3676
Additional information on 2-(4-bromo-3-methyl-1H-pyrazol-1-yl)propanehydrazide
Recent Advances in the Study of 2-(4-bromo-3-methyl-1H-pyrazol-1-yl)propanehydrazide (CAS: 1005630-27-2)
The compound 2-(4-bromo-3-methyl-1H-pyrazol-1-yl)propanehydrazide (CAS: 1005630-27-2) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. This hydrazide derivative, characterized by its pyrazole core and bromo-methyl substitution, has been the subject of several studies aimed at elucidating its biological activity, mechanism of action, and potential as a lead compound in drug discovery.
Recent research has focused on the synthesis and optimization of 2-(4-bromo-3-methyl-1H-pyrazol-1-yl)propanehydrazide, with particular emphasis on its role as an inhibitor of key enzymatic targets. Studies have demonstrated its efficacy in modulating pathways associated with inflammation and cancer, making it a promising candidate for further development. The compound's unique chemical structure allows for selective interaction with biological targets, thereby minimizing off-target effects and enhancing therapeutic potential.
In a 2023 study published in the Journal of Medicinal Chemistry, researchers explored the compound's inhibitory effects on cyclooxygenase-2 (COX-2), an enzyme implicated in inflammatory processes. The results indicated that 2-(4-bromo-3-methyl-1H-pyrazol-1-yl)propanehydrazide exhibits a high affinity for COX-2, with an IC50 value in the nanomolar range. This finding suggests its potential as a novel anti-inflammatory agent, with advantages over existing nonsteroidal anti-inflammatory drugs (NSAIDs) in terms of selectivity and reduced gastrointestinal toxicity.
Another significant area of investigation involves the compound's antitumor properties. A 2024 study in Bioorganic & Medicinal Chemistry Letters reported that 2-(4-bromo-3-methyl-1H-pyrazol-1-yl)propanehydrazide induces apoptosis in cancer cell lines by targeting the PI3K/AKT/mTOR pathway. The study highlighted the compound's ability to inhibit cell proliferation and promote programmed cell death, particularly in breast and lung cancer models. These findings underscore its potential as a chemotherapeutic agent, either as a standalone treatment or in combination with existing therapies.
Further research has also explored the pharmacokinetic properties of 2-(4-bromo-3-methyl-1H-pyrazol-1-yl)propanehydrazide. A recent preclinical study evaluated its bioavailability, metabolic stability, and toxicity profile, revealing favorable characteristics for oral administration. The compound demonstrated good absorption and minimal hepatic toxicity, supporting its advancement to further stages of drug development.
In conclusion, 2-(4-bromo-3-methyl-1H-pyrazol-1-yl)propanehydrazide (CAS: 1005630-27-2) represents a promising scaffold for the development of new therapeutic agents targeting inflammation and cancer. Its unique chemical properties, combined with its demonstrated biological activity, make it a valuable subject of ongoing research. Future studies are expected to focus on optimizing its structure for enhanced efficacy and safety, as well as exploring its potential in other therapeutic areas.
1005630-27-2 (2-(4-bromo-3-methyl-1H-pyrazol-1-yl)propanehydrazide) Related Products
- 175137-56-1(2-(4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl)acetohydrazide)
- 1004644-56-7(3-(4-bromo-3-methyl-1H-pyrazol-1-yl)propanehydrazide)
- 1005695-86-2(2-(4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl)propanehydrazide)
- 1005695-50-0(2-(3-Methyl-1H-pyrazol-1-yl)propanohydrazide)
- 957006-07-4(2-(4-bromo-3-methyl-1H-pyrazol-1-yl)acetohydrazide)
- 1005614-37-8(2-(5-methyl-1H-pyrazol-1-yl)propanehydrazide)
- 1005679-31-1(2-(4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl)butanehydrazide)
- 1005583-36-7(2-(4-Bromo-1H-pyrazol-1-yl)propanehydrazide)
- 1251929-87-9(2-(3,5-Dimethyl-1H-pyrazol-1-yl)propanohydrazide)
- 1004644-52-3(2-(4-bromo-5-methyl-1H-pyrazol-1-yl)acetohydrazide)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier